Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Fatigue × Valganciclovir × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Herpes Simplex 1 Glioblastoma 1 Fatigue Syndrome, Chronic 1 Fatigue 1 Epstein-Barr Virus Infections 1

Interventions

isoquercitrin 1 Valganciclovir 1 Tai Ji 1 Sunitinib 1 Qigong 1 Psychiatric Rehabilitation 1 Homeopathy 1 Exercise Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00478465 2022-05-27

Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)

Stanford University

Phase 1/2 Completed

Fatigue, Herpes Simplex, Fatigue Syndrome, Chronic, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡